Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2023-05-04 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated May 4, 2023, announcing that MedinCell's partner, Teva, will present pharmacokinetic analysis data for a long-acting injectable formulation (mdc-TJK) at the SIRS 2023 conference. It discusses clinical trial progress (Phase 1 and Phase 3 initiation), recent FDA approval of a related product (UZEDY™), and provides company background and forward-looking statements. This type of announcement, detailing scientific updates, clinical progress, and partnership milestones, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on results/updates that often accompany earnings periods or significant corporate events, 'ER' (Earnings Release) is the most appropriate classification for a major corporate announcement of clinical/pipeline progress, even if it's not strictly quarterly results. Given the context of presenting new data and pipeline updates, it functions as a significant corporate disclosure. FY 2023
2023-05-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated May 4, 2023, announcing that pharmacokinetic data from a Phase 1 clinical study for a drug candidate (mdc-TJK) will be presented by Teva at the SIRS 2023 conference. It discusses clinical trial progress, FDA approval of a related product (UZEDY™), and includes standard 'About' and 'Contacts' sections typical of corporate news releases. This type of announcement, detailing upcoming scientific presentations or key operational updates outside of mandatory financial reporting cycles (like 10-K or 10-Q), is best classified as a general Regulatory Filing or News Release, as it doesn't fit the specific definitions for Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Since it is a general corporate announcement that doesn't fit the highly specific categories like DIRS, DIV, or DEF 14A, the most appropriate fallback is Regulatory Filings (RNS).
2023-05-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated May 2, 2023, announcing the first FDA approval for MedinCell's product (mdc-IRM, marketed as UZEDY™) and the subsequent commercial launch in the US. It details financial implications (royalties, milestones) and includes quotes from management. This type of announcement, focusing on key financial and operational achievements outside of a mandated periodic report (like 10-K or IR), is characteristic of an Earnings Release (ER) or a significant corporate event announcement. Since it is a formal announcement of results/achievements rather than a full quarterly report (IR) or a transcript (CT), and it focuses on the immediate financial impact of a major event, 'ER' (Earnings Release) is the most appropriate fit, as these releases often cover major operational milestones alongside financial updates, especially for smaller companies where major product news drives the 'earnings' narrative. It is not a proxy statement (DEF 14A), a full annual report (10-K), or a simple dividend notice (DIV). Given the context of a major product launch and associated financial milestones, it functions as a significant corporate update often grouped with ERs.
2023-05-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated May 2, 2023, announcing a major corporate event: the FDA approval of a product (UZEDY™) and the subsequent US commercial launch. It details financial implications (royalties, milestones, loan tranches) and includes quotes from the CEO and CFO. This type of announcement, focusing on significant operational and financial milestones outside of routine quarterly reporting (like 10-Q or 10-K), is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a detailed announcement of key results and future outlook following a major event (FDA approval), it aligns best with the 'Earnings Release' category, which often covers significant operational achievements alongside financial impacts, even if it's not strictly a quarterly earnings report. It is too detailed for a simple RPA or RNS, and it is not a full financial report (IR/10-K). Given the focus on commercial progress and financial triggers, ER is the most appropriate fit among the provided options for a major corporate milestone announcement.
2023-05-02 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated April 28, 2023, announcing the FDA approval of a new drug, UZEDY, by Teva Pharmaceuticals and MedinCell. It details the drug's benefits, clinical trial results (RISE and SHINE studies), and provides contact information for Investor Relations (IR) and Public Relations (PR). This type of announcement, which communicates significant business/product news and financial/operational milestones outside of mandated periodic reports (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or a Regulatory Filing (RNS) if it's a general announcement. Since this is a major product approval announcement containing key efficacy data and market context, it functions as a primary communication of recent business performance/developments, fitting best under the 'Earnings Release' category, which often encompasses major press releases regarding operational milestones, even if specific quarterly financials aren't the primary focus. It is not a full report (10-K, IR), a transcript (CT), or a management discussion (MDA). Given the context of major corporate news dissemination, ER is the most appropriate fit among the options provided for a significant, non-periodic corporate announcement.
2023-04-29 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 28, 2023, announcing the US FDA approval of a new drug, UZEDY, by Teva and MedinCell. It details the drug's mechanism, clinical trial results, pricing information, and includes standard 'About Us' sections for both companies. This type of announcement, focusing on a significant corporate event (drug approval) and providing key financial/product details, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of a major event rather than just a summary of quarterly financials (ER) or a miscellaneous regulatory notice (RNS), and given the context of pharmaceutical news, it most closely aligns with a major corporate announcement. However, among the provided codes, it is not a specific financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or DVA). It is a comprehensive announcement of a major business development. Since it is not a short announcement pointing to an attached report (ruling 2), it is not RPA. It is a detailed press release. In the context of financial databases, major product/regulatory milestones are often categorized under the closest relevant category or as a general regulatory filing. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that don't fit the other specific financial/meeting codes. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Discussion (MDA). I will classify it as RNS as a comprehensive regulatory/corporate milestone announcement.
2023-04-29 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.